Plaque psoriasis prospect roflumilast predicted to launch in 2022

21 May 2021

GlobalData has taken a look at the data supporting roflumilast for plaque psoriasis (PsO).

US biotech Arcutis Biotherapeutics (Nasdaq: ARQT) announced new data from its pivotal DERMIS-1 and DERMIS-2 studies on the topical phosphodiesterase-4 (PDE4) inhibitor at the EADV Spring Symposium.

"Roflumilast would be Arcutis’ first agent to market and will compete with agents coming from pharmaceutical stalwarts such as AbbVie and Johnson & Johnson"Tiffany Chan, immunology analyst at GlobalData, said: “In the announced clinical trial results, roflumilast cream was generally safe and well tolerated. In fact, 90% of patients within the randomized roflumilast treatment arm completed a full eight weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK